Isoxanthopterin
(Synonyms: 異黃喋呤,NSC 118090,NSC 614991) 目录号 : GC10834
An intermediate in the pteridine pathway
Cas No.:529-69-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Isoxanthopterin interferes with RNA and DNA synthesis.
Isoxanthopterin, a natural intermediate in the pteridine pathway, plays critical roles in pigmentation and cell division.
In vitro: Isoxanthopterin was identified as a pteridine of wide natural occurrence and was reported to exerts an inhibitory action on the synthesis of ribosomal RNA, possibly soluble RNA and on DNA in developing eggs of the milkweed bug Oncopeltus fasciatus. Such effects were measured by partially incubating dechorionated eggs in a solution containing isoxanthopterin and radioactive uridine or thymidine, and then testing the incorporation of the isotope into ribosomal RNA or DNA. The detailed mechanism of this inhibition had been discussed, and the tentative conclusion was agreed that it was due to an interaction between the pteridine and the nucleic acid (most probably DNA) [1].
In vivo: Previous animal study showed that rats with inherited retinal dystrophy appeared to differ from healthy rats by an elevated isoxanthopterin excretion in urine. RCS rats responded to feeding of monapterin with an increase of isoxanthopterin excretion. This phenomenon supported the idea that the RCS rat had an increased xanthinoxidase activity compared with healthy rats [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Lagowski, J. M. and Forrest, H.S. Interaction in vitro between isoxanthopterin and DNA. Proceedings of the National Academy of Sciences of the United States of America 58(4), 1541-1547 (1967).
[2] G. Cremer-Bartels, H. Gerding, L. Hanneken and K. Krause. Isoxanthopterin Excretion of Rats with Inherited Retinal Dystrophy. Pteridines Vol. 2, 1990, pp. 103 -105.
| Cas No. | 529-69-1 | SDF | |
| 别名 | 異黃喋呤,NSC 118090,NSC 614991 | ||
| 化学名 | 2-amino-4,7(3H,8H)-pteridinedione | ||
| Canonical SMILES | O=C1C=NC(C(N=C(N)N2)=O)=C2N1 | ||
| 分子式 | C6H5N5O2 | 分子量 | 179.1 |
| 溶解度 | ≤5mg/L in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.5835 mL | 27.9174 mL | 55.8347 mL |
| 5 mM | 1.1167 mL | 5.5835 mL | 11.1669 mL |
| 10 mM | 0.5583 mL | 2.7917 mL | 5.5835 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。